<circle stroke="#1e77f9" class="srdi68r9" cx="25" cy="25" r="20" fill="none" stroke-width="5">

Dynavax jumps 37% to $15.31 after buyout offer from Sanofi

PremiumThe Fly

5d ago

Sanofi to acquire Dynavax for $15.50 per share in cash, or $2.2B

DVAX

PremiumThe Fly

5d ago

Sanofi announces European Commission approval of Wayrilz

DVAX

PremiumThe Fly

6d ago

Regeneron, Sanofi get marketing authorization for Dupixent from MHLW in Japan

PremiumThe Fly

6d ago

REGN

PremiumThe FlyGovernment deals lift overhang on pharma group, says BofA

7d ago

Trump announces pacts with nine pharma companies to lower drug prices

The Fly

Trump announces pacts with nine pharma companies to lower drug prices

9d ago

GSK

Drugmakers set to make deals with Trump in exchange for incentives, WaPo reports

The Fly

Drugmakers set to make deals with Trump in exchange for incentives, WaPo reports

9d ago

Sanofi anticipates delay in U.S. regulatory review of tolebrutinib in nrSPMS

PremiumThe Fly

14d ago

Sanofi says tolebrutinib did not meet primary endpoint in PERSEUS phase 3 study

PremiumThe Fly

14d ago

Sanofi: Buy Rating Maintained Amid Attractive Valuation and Long-Term Growth Potential Despite Pipeline Setbacks

PremiumRatings

14d ago

Sanofi says Qfitlia, Cablivi approved in China for rare hematologic diseases

PremiumThe Fly

18d ago

PremiumThe FlySanofi price target lowered to EUR 100 from EUR 102 at HSBC

19d ago

Guggenheim downgrades Sanofi on lack of near-term pipeline catalysts

The Fly

Guggenheim downgrades Sanofi on lack of near-term pipeline catalysts

20d ago

Sanofi downgraded to Neutral from Buy at Guggenheim

The Fly

Sanofi downgraded to Neutral from Buy at Guggenheim

20d ago

Sanofi downgraded to Neutral from Overweight at JPMorgan

PremiumThe Fly

21d ago

Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’

PremiumThe Fly

23d ago

PremiumThe Fly

FDA shift in drug study requirements sends trial runners lower

25d ago

FDA to reduce number of trials required for drug approvals, STAT reports

PremiumThe Fly

25d ago

PremiumThe FlyFDA to reduce number of trials required for drug approvals, STAT reports

25d ago

Top drug regulator Richard Pazdur preparing to exit FDA, STAT News reports

The Fly

Top drug regulator Richard Pazdur preparing to exit FDA, STAT News reports

26d ago

Vaccine committee considers changes to childhood schedule, NY Times reports

The Fly

Vaccine committee considers changes to childhood schedule, NY Times reports

27d ago